Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A cross-over double-blind trial was conducted in 14 patients (20 double-blind treatment courses) comparing domperidone and placebo in the treatment of vomiting due to intensive cytostatic treatment. Eight ml, containing 16 mg of domperidone or placebo was injected one hour before the start of cytostatic therapy. The efficacy of the drug was evaluated by the investigator and the duration of nausea and vomiting was registered in the majority of the patients. Domperidone was preferred to placebo 13 times, whereas the reverse preference occurred only twice. The duration of both nausea (a median of 11 hours against seven hours) and vomiting (a median of 7 1/2 hours against 6 hours) was shorter with domperidone than with the placebo.
 ...
PMID:Cytostatic therapy-induced vomiting inhibited by domperidone. A double-blind cross-over study. 37 90

The effect of domperidone on vomiting due to cytostatic treatment was studied during a double-blind trial involving 41 patients. One group received the sequence domperidone-placebo and the other the reverse sequence during two consecutive courses of cytostatic therapy (chlormethine alone or in combination with other cytostatics). Domperidone 2 mg/ml or the placebo was injected IV 1 h before the start of the cytostatic treatment. A similar injection was given 4 h later. Presence, duration, and incidence of nausea and vomiting before, during, and after the peak period (period from the second up to and including the sixth hour after cytostatic injection) were measured. With respect to vomiting, domperidone was significantly superior to placebo concerning duration and effect before and after the peak period in both sequences. There was no difference during the peak period. With respect to nausea, domperidone was superior to placebo concerning duration and effect during the peak period in the placebo-domperidone sequence. No difference was observed in the reverse order. A significant superiority of domperidone was noted before the peak period.
 ...
PMID:Cytostatic-associated vomiting effectively inhibited by domperidone (R 33 812). 37 21

The findings of a study into the anti-emetic properties of domperidone are reported. When the drug was given prophylactically with either morphine or pethidine the study revealed that any anti-emetic property of domperidone was of short duration and that it would not be suitable as a prophylaxis against opiate-induced emesis. Domperidone is not being introduced into clinical practice in the United Kingdom on the basis of current study.
 ...
PMID:Evaluation of the anti-emetic action of domperidone. 52 33

Domperidone was compared with placebo in a multicenter double-blind study of 116 patients (15 to 80 years) with postoperative vomiting. After vomiting had occurred, the patients received either domperidone 10 mg or placebo IV. Patients were then followed for at least 6 hours or until a 2nd injection of domperidone 10 mg from an open supply was needed. The period of time until an additional injection was registered and compared between the 2 treatment groups. Fifty-nine percent of the placebo patients needed a 2nd injection before the end of the 6-hour follow-up, compared with only 35% of the domperidone patients (p less than 0.05). When a 2nd injection was required, the time elapsed before it was needed was longer (p = 0.01) in the domperidone group (median 150 minutes) than in the placebo one (median 120 minutes). There were no significant side-effects.
 ...
PMID:Domperidone in the treatment of postoperative vomiting: a double-blind multicenter study. 56 95

Dopamine antagonists are effective anti-emetics. Domperidone does not readily cross the blood-brain barrier and is less likely to cause central nervous system side-effects than metoclopramide. However, a direct comparison of the safety and efficacy of the two drugs has not hitherto been made. Ninety-five patients, with symptoms of nausea and vomiting due to a variety of oesophageal or gastric disorders, were recruited into a randomised, double-blind, three-part, parallel-group comparative study of controlled release metoclopramide 15 mg (Gastrobid Continus tablets, Napp Laboratories) given twice daily, and domperidone 10 mg or 20 mg given three times daily. Assessments for nausea, vomiting, reflux symptoms and adverse events were made on entry to the study. Patients were randomly allocated to one of the three treatment regimes for a period of seven days, throughout which daily symptomatology and use of escape medication were recorded on a diary card. At the end of the treatment period, nausea, vomiting and reflux symptoms, adverse events and a global assessment of patients' symptom control were recorded by the investigator. Both controlled release metoclopramide and high and low dose domperidone significantly reduced symptoms of belching, flatulence, distension, heartburn, regurgitation, reflux, nausea and vomiting compared to baseline. There were no significant differences between the three treatments in efficacy or in the number and severity of side-effects.
 ...
PMID:A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting. 181 Mar 56

Domperidone has been used as a gastrokinetic and anti-emetic drug within the frames of an intensive care programme in 57 patients with a history of 3-4 days of acute myocardial infarction. According to the observations, Motilium prevents the development of gastroduodenal complaints and nausea, vomiting in a period following the first days of acute therapy and promotes the start of bowel movement and defecation. It has no cardiac or other toxic effects and does not influence the action of other drugs.
 ...
PMID:Role of domperidone in improving intestinal activity in acute myocardial infarction patients. 181 29

The pathophysiology, diagnosis, and treatment of diabetic gastroparesis are reviewed, and the mechanisms of action, pharmacokinetics, clinical efficacy, adverse effects, and dosage of metoclopramide, domperidone, and cisapride are described. Diabetic gastroparesis is a state of delayed gastric emptying that reportedly affects 20-30% of diabetic patients. Symptoms include nausea, early satiety, postprandial bloating and fullness, and vomiting. Diabetic gastroparesis has been managed most successfully with drugs that stimulate gastric emptying. Of the three agents studied--metoclopramide, domperidone, and cisapride--only metoclopramide is commercially available in the United States. The clinical efficacy of metoclopramide, domperidone, and cisapride has been well documented in several placebo-controlled trials. Metoclopramide effectively decreases mean gastric emptying time, although tolerance to this stimulation of gastric emptying may develop with long-term therapy. However, symptomatic relief persists with long-term therapy because of metoclopramide's antiemetic properties. Domperidone, which has also been shown to stimulate gastric motility and to possess antiemetic properties, improves symptoms in patients suffering from diabetic gastroparesis. Cisapride appears to have continued beneficial effects on gastric motility with long-term therapy. All three agents have favorable adverse-effect profiles. Although metoclopramide is currently the first-line agent for the management of gastroparesis, domperidone and cisapride both possess properties that may make them useful alternatives in patients who are unresponsive to or cannot tolerate metoclopramide therapy.
 ...
PMID:Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesis. 219 Jul 45

Domperidone is useful in the treatment of vomiting and gastroesophageal reflux in children. Its efficaciousness is due to the antagonist effect on gastrointestinal dopaminergic receptors. Contrary to the initial expectations, domperidone is able to penetrate into the hematoencephalic barrier and to cause adverse neurologic reactions. We report a case of extrapyramidal reaction in a child after moderate overdosage of domperidone.
 ...
PMID:[Extrapyramidal syndrome caused by moderate overdosage of domperidone. Description of a case]. 223 67

1. The aim of this study is to review the mechanisms implicated in nausea and vomiting and the treatment of these symptoms. 2. Metoclopramide, a benzamide, is the drug most frequently used to alleviate or abolish the majority of nausea and vomiting of different origin. Domperidone, which scarcely penetrates the central nervous system (CNS), is less used. 3. The treatment of vomiting induced by cytotoxic drugs is necessary to use a combination (two or more) of antiemetic drugs (metoclopramide, glucocorticoids, antihistamines, butyrophenones, anticholinergics, cannabinoids). Recently, antagonists of serotonergic (5-HT) receptors of the subtype 5-HT3 appear to possess interesting antiemetic properties and they have a promising future in this field. 4. Antagonists of dopamine receptors (benzamides, phenotiazines, butyrophenones and domperidone) induce adverse reactions in CNS (mainly extrapyramidal disorders), which are scarce with metoclopramide and practically absent with domperidone. These disorders must not suppress antiemetic therapy when it is needed.
 ...
PMID:Therapeutic management of nausea and vomiting. 240 30

The gastrointestinal motor correlates of vomiting consist of two contractile events, 1) a giant retrogradely propagated contraction of the upper small intestine, the retrograde giant contraction (RGC) and 2) a series of post-RGC phasic contractions that occur primarily in the lower small intestine. The effects of cholinergic, dopaminergic, serotonergic, and opioid receptor antagonists and an opioid receptor agonist on vomiting and its gastrointestinal motor correlates initiated by apomorphine (APO), CuSO4, or cholecystokinin octapeptide (CCK-8) were determined in awake dogs. Atropine blocked the retrograde giant contraction only, and hexamethonium blocked all jejunoileal motor responses activated by APO, CuSO4, or CCK-8. Domperidone blocked all effects of APO only, whereas haloperidol, methysergide, 1-(1-naphthyl) piperazine, and fentanyl blocked or inhibited responses to both APO and CuSO4. None of the dopaminergic, serotonergic, or opioid receptor antagonists or the opioid receptor agonist affected the gastrointestinal motor responses to CCK-8. Cinanserin or Sch 23390 had no effect on any of the responses activated by APO, CuSO4, or CCK-8. These results suggested that D2 dopaminergic and 5-HT2 serotonergic receptors of the emetic central pattern generator mediate vomiting and its gastrointestinal motor correlates, whereas opioid receptors may mediate tonic inhibition of these responses. In addition, peripheral muscarinic or nicotinic cholinergic receptors but not peripheral 5-HT2, dopaminergic, or opioid receptors mediate the gastrointestinal motor correlates of vomiting.
 ...
PMID:Functional localization of specific receptors mediating gastrointestinal motor correlates of vomiting. 256 2


1 2 3 4 5 Next >>